Intervention

Tumor Infiltrating Lymphocytes (TIL)

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting4

Common conditions18

Lead sponsors shown2

Clinical trials

4 shown

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerNCT06532799 · 2024-09-10

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerNCT06532812 · 2024-08-22

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerNCT06538012 · 2024-08-20

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)NCT05142475 · 2021-11-19

Common conditions

Breast Cancer2 Advanced Breast Cancer1 Breast Cancer Metastatic1 Breast Cancer Triple Negative1 Breast Carcinoma1 Effects of Immunotherapy1 Esophageal Cancer1 Esophageal Cancer Metastatic to Bone1 Esophageal Cancer Metastatic to Liver1 Esophageal Cancer Metastatic to Lung1 Lung Cancer1 Lung Cancer Metastatic1 Lung Cancer Recurrent1 Lung Cancer, Non-small Cell1 Stomach Cancer1 Stomach Cancer Recurrent1 Stomach Cancer, Adenocarcinoma1 Treatment Side Effects1

Leading sponsors

Essen Biotech3 Shanghai Juncell Therapeutics1

Trial status mix

RECRUITING4

Phase mix

PHASE13

PHASE23

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.